Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.75 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.75 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.75 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.75 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.75 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.75 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.75 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.75 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRE | P78334 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1967312 | 0.98 | GABRA5 (0.72) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL17275233 | 0.93 | SLC6A12 (0.67) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL5495206 | 0.91 | SLC6A1 (0.64) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL8131617 | 0.88 | GABRA5 (0.60) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL24478321 | 0.86 | — | — | |
| SCHEMBL374930 | 0.86 | — | — | |
| SCHEMBL2450833 | 0.86 | — | — | |
| SCHEMBL8791493 | 0.84 | SLC6A12 (0.56) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL22655757 | 0.84 | SLC6A1 (0.96) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL21774701 | 0.84 | SLC6A1 (0.96) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119306698-A | Novel method for preparing zavigpam intermediate | 浙江工业大学 | 2025-01-14 | — | — | CN | claimed |
| US-20240092849-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2024-03-21 | — | — | US | claimed |
| CN-114621088-B | Preparation method of diethyl terephthalamide | 安徽新秀化学股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-117050061-A | 2,4, 6-tri (piperidinecarboxylic acid) -1,3,5 triazine and preparation method thereof | 济南利恒生物科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| EP-4236942-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| EP-4236937-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| WO-2022093850-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022093849-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| CN-108586178-B | Process for the manufacture of nitriles and their corresponding amines | 中国石油化工股份有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-20190077840-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | NATIONAL INSTITUTES OF HEALTH | 2019-03-14 | — | — | US | claimed |
| CN-101035520-A | CRP lowering agent | TAKEDA PHARMACEUTICAL (JP) | 2007-09-12 | — | — | CN | claimed |
| CN-101001854-A | Highly selective novel amidation method | TAKEDA PHARMACEUTICAL (JP) | 2007-07-18 | — | — | CN | claimed |
| EP-1753752-A1 | HIGHLY SELECTIVE NOVEL AMIDATION METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-02-21 | — | — | EP | claimed |
| US-7169759-B1 | Tetrapeptide inhibitors of β-secretase | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-30 | — | — | US | claimed |
| CN-1738805-A | N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidincarboxamid-derivatives and related compounds use as CGRP-antagonists for treating a headache | BOEHRINGER INGELHEIM INT (DE) | 2006-02-22 | — | — | CN | claimed |
| WO-2005121133-A1 | HIGHLY SELECTIVE NOVEL AMIDATION METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-22 | — | — | WO | claimed |
| CN-1473053-A | High-density lipoprotein-cholesterol level elevating agent | ����ҩƷ��ҵ��ʽ���� | 2004-02-04 | — | — | CN | claimed |
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | claimed |
| EP-1192177-A1 | STATINE-DERIVED TETRAPEPTIDE INHIBITORS OF BETA-SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| WO-2000077030-A1 | STATINE-DERIVED TETRAPEPTIDE INHIBITORS OF BETA-SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2000-12-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | GABRA5 2112/4885GABRB2 2640/4885SLC6A1 3219/4885 |
| US-20190077840-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | MCL1, BCL2L11, BCL2L1 | GABRA5 4263/4885GABRB2 3705/4885SLC6A1 4624/4885 |
| US-20240092849-A1 | SELECTIVE MCL-1 BINDING PEPTIDES | MCL1, BCL2L11, BCL2L1 | GABRA5 4263/4885GABRB2 3705/4885SLC6A1 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.